Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs and identify candidates against additional targets.